PHARMACOLOGICAL AND MORPHOLOGICAL FEATURES AND SOCIOECONOMIC ASPECTS OF CANNABIDIOL: A LITERATURE REVIEW

Олесь-Пилип Гасюк

doi:10.61751/ijmmr.2413-6077.2023.1.47

Автор(и)

Олесь-Пилип Гасюк Львівський національний медичний університет імені Данила Галицького https://orcid.org/0009-0007-9456-4526

DOI:

https://doi.org/10.61751/ijmmr.2413-6077.2023.1.47

Ключові слова:

канабіс, токсикологія, право, епілепсія, хронічний біль

Анотація

Через зростаючу популярність непсихоактивної речовини продуктів коноплі як лікувального засобу, необхідно було провести детальний аналіз наявних наукових досліджень з теми впливу канабідіолу на людський організм. Метою цього огляду був збір та систематизація інформації про позитивні та негативні впливи канабідіолу, а також про можливості його використання в медицині. Проведений аналіз 3375 наукових статей, публікацій і звітів, з яких відібрано 68 тих, що найбільше відповідали умовам запиту. Зібрані дані були узагальнені і представлені в структурованому форматі. Отримані результати огляду вказують на значний фармакологічний потенціал канабідіолу, який може використовуватися, як перспективний терапевтичний засіб у різних медичних сферах. В розглянутих дослідженнях канабідіол виявляв протисудомний, протиепілептичний ефект, а також позитивний вплив в програмах заміни наркотичних речовин. Проте також було відзначено можливість негативних реакцій та потенційно шкідливого впливу канабідіолу: може призводити до розвитку психологічної та фізичної залежності; підвищує ризик розвитку фізіологічних порушень, зокрема вплив на сперматогенез та порушення жіночої мікрофлори; впливає на поведінку та призводить до відхилень у розвитку. Дія канабідіолу на організм людини досі залишається недостатньо вивченою, а його розповсюдження в умовах недостатнього законодавчого регулювання може чинити ризик для здоров'я та безпеки споживачів. Розуміння всіх аспектів використання канабідіолу забезпечить належне управління його використанням і розвитком відповідної законодавчої бази, а також сприятиме подальшому вивченню та розробці нових препаратів на основі даного рослинного екстракту

Отримано: 17.02.2023 | Переглянуто: 26.04.2023 | Прийнято: 30.05.2023

Біографія автора

Олесь-Пилип Гасюк, Львівський національний медичний університет імені Данила Галицького

Доктор медицини, старший лаборант 79010, вул. Пекарська, 69, м. Львів, Україна

Посилання

Zaychenko GV, Simonov PV. Medical cannabis and cannabinoids in clinical practice: Pharmacological effects and risks. Health Technol Assessm. 2019;2(2):13 –17. Available from: https://librarynmu.com/images/PDFfile/Zaichenko.pdf

Hinz B, Ramer R. Anti-tumour actions of cannabinoids. Br J Pharmacol. 2019;176(10):138–94. DOI: 10.1111/bph.14426

Sulaieva O, Mashukov A, Kirkilevsky S. The tumour immune contexture and theranostic markers expression in patients with gastric carcinoma. Ann Oncol. 2020;31(Suppl 4):1115. DOI: 10.1016/j.annonc.2020.08.1300

Aliekperova N, Kosyachenko К, Kaniura O. Perspectives on formation of medical cannabis market in Ukraine based on holistic approach. J Cannabis Res. 2020;2:33. DOI: 10.1186/s42238-020-00044-y

Aliekperova N, Kostiuk I, Hala L, Biliaeva A. Pharmacists’ opinions on the legalization of medical cannabis in Ukraine. Research J. Pharm. and Tech. 2023;16(4):1851–56. DOI: 10.52711/0974-360X.2023.00303

Singh C, Rao K, Yadav N, Vashist Y, Chugh P, Bansal N, et al. Current cannabidiol safety: A review. Curr Drug Saf. 2023;18(4):465–73. DOI: 10.2174/1574886317666220902100511

Liu L, Liu J, Zhao M, Cai M, Lei F, Zeng X, Zhu B. A bibliometrics and visualization analysis of cannabidiol research from 2004 to 2021. Front Pharmacol. 2022;13:969883. DOI: 10.3389/fphar.2022.969883

Amin MR, Ali DW. Pharmacology of medical cannabis. Adv Exp Med Biol. 2019;1162:151–65. DOI: 10.1007/978-3-030-21737-2_8

Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. J Am Chem Soc. 1940;62(1):196–200. DOI: 10.1021/ja01858a058

Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Use of cannabidiol in the treatment of epilepsy: Efficacy and security in clinical trials. Molecules. 2019;24(8):1459. DOI: 10.3390/molecules24081459

Parker LA, Rock EM, Mechoulam R. CBD: What Does the Science Say? [Internet]. Cambridge: The MIT Press; 2022 [cited 2023 Aug 17]. 320 p. DOI: 10.7551/mitpress/13686.001.0001

Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Della Pina S, et al. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life Sci. 2019;224:120–27. DOI: 10.1016/j.lfs.2019.03.053

Raïch Iu, Rivas-Santisteban R, Lillo A, Lillo J, Reyes-Resina I, Nadal X, et al. Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors. Pharmacol Res. 2021;174:105970. DOI: 10.1016/j.phrs.2021.105970

Bosquez-Berger T, Gudorf JA, Kuntz CP, Desmond JA, Schlebach JP, VanNieuwenhze MS, Straiker A. Structure-activity relationship study of cannabidiol-based analogs as negative allosteric modulators of the μ-opioid receptor. J Med Chem. 2023;66(14):9466–94. DOI: 10.1021/acs.jmedchem.3c00061

Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology. 2019;74:282–98. DOI: 10.1016/j.neuro.2019.08.002

Martin LJ, Banister SD, Bowen MT. Understanding the complex pharmacology of cannabidiol: Mounting evidence suggests a common binding site with cholesterol. Pharmacol Res. 2021;166:105508. DOI: 10.1016/j.phrs.2021.105508

Khalsa JH, Bunt G, Blum K, Maggirwar SB, Galanter M, Potenza MN. Review: Cannabinoids as medicinals. Curr Addict Rep. 2022;9(4):630–46. DOI: 10.1007/s40429-022-00438-3

Luz-Veiga M, Azevedo-Silva J, Fernandes JC. Beyond pain relief: A review on cannabidiol potential in medical therapies. Pharmaceuticals. 2023;16(2):155. DOI: 10.3390/ph16020155

della Rocca G, Paoletti F, Conti MB, Galarini R, Chiaradia E, Sforna M, et al. Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs. Front Vet Sci. 2023;9:1104152. DOI: 10.3389/fvets.2022.1104152

Ruiz CM, Torrens A, Lallai V, Castillo E, Manca L, Martinez MX, et al. Pharmacokinetic and pharmacodynamic properties of aerosolized (“vaped”) THC in adolescent male and female rats. Psychopharmacology. 2021;238(12):3595–5. DOI: 10.1007/s00213-021-05976-8

Bardhi K, Coates S, Watson CJW, Lazarus P. Cannabinoids and drug metabolizing enzymes: Potential for drug-drug interactions and implications for drug safety and efficacy. Expert Rev Clin Pharmacol. 2022;15(12):1443–60. DOI: 10.1080/17512433.2022.2148655

Batinic A, Sutlovic D, Kuret S, Burcul F, Kalajzic N, Matana A, et al. Differences in plasma cannabidiol concentrations in women and men: A randomized, placebo-controlled, crossover study. Int J Mol Sci. 2023;24(12):10273. DOI: 10.3390/ijms241210273

Rao Q, Zhang T, Dai M, Li B, Pu Q, Zhao M, et al. Comparative metabolomic profiling of the metabolic differences of Δ9-tetrahydrocannabinol and cannabidiol. Molecules. 2022;27(21):7573. DOI: 10.3390/molecules27217573

Vlad RA, Hancu GH, Ciurba A, Antonoaea P, Rédai EM, Todoran N, et al. Cannabidiol – therapeutic and legal aspects. Pharmazie. 2020;75(10):463–69. DOI: 10.1691/ph.2020.0076

FDA. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD) [Internet]. 2023 [cited 2023 Jul 15]. Available from: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd

Chu W. Nutra Ingredients Europe. Updated EC Ruling for CBD as Novel Food [Internet]. 2019 [cited 2023 Jul 15]. Available from: https://www.nutraingredients.com/Article/2019/01/31/Updated-EC-ruling-for-CBD-classes-supplement-ingredient-as-Novel-Food

International Narcotics Control Board. Reports 2021 [Internet]. 2022 [cited 2023 Jul 15]. Available from: https://www.incb.org/documents/Publications/AnnualReports/AR2021/Annual_Report/E_INCB_2021_1_eng.pdf

Poperechna D. Medical cannabis usage has been legalized in Ukraine, but not entirely. Ukrainian Pravda [Internet]. 2021 Apr 9 [cited 2023 Jul 15]. Available from: https://life.pravda.com.ua/health/2021/04/9/244505/

Fortin D, Di Beo V, Massin S, Bisiou Y, Carrieri P, Barré T. Reasons for using cannabidiol: A cross-sectional study of French cannabidiol users. J Cannabis Res. 2021;3(1):46. DOI: 10.1186/s42238-021-00102-z

Gibbs B, Yates DA, Liebling J. CBD in the UK: Towards a responsible, innovative and high-quality cannabidiol industry. Centre for Medicinal Cannabis [Internet]. 2019 Jun [cited 2023 Jul 15]. 72 p. Available from: https://hempindustrydaily.com/wp-content/uploads/2020/04/Report-_-CBD-in-the-UK-002.pdf

Bisiou Y. Drugs, cannabis and cannabidiol (CBD): France under pressure from the CJEU. 2021. Available from: https://www.researchgate.net/publication/349454809_Stupefiants_cannabis_et_cannabidiol_CBD_la_France_sous_pression_de_la_CJUE

Dierking D. MJUS vs. MSOS: Which U.S. Cannabis market ETF looks better? ETF Focus. [Internet]. 2021 Jun 21 [cited 2023 Jul 15]. Available from: https://www.thestreet.com/etffocus/trade-ideas/mjus-msos-which-cannabis-etf-looks-better

Englund A, Oliver D, Chesney E, Chester L, Wilson J, Sovi S, et al. Does cannabidiol make cannabis safer? A randomized, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacol. 2023;48(4):869–76. DOI: 10.1038/s41386-022-01478-z

Cannabidiol Global Market Report 2023. Report [Internet]. 2023 Feb [cited 2023 Jul 15]. 200 p. Available from: https://www.researchandmarkets.com/reports/5741562/cannabidiol-global-market-report

Kaufmann R, Harris Bozer A, Kube Jotte A, Aqua K. Long-Term, Self-Dosing CBD Users: Indications, dosage, and self-perceptions on general health/symptoms and drug use. Med Cannabis Cannabinoids. 2023;6(1):77–88. DOI:10.1159/000531666

Roser P, Habermeyer B, Scherbaum N, Lay B. Cannabidiol use among patients with substance use disorders. Subst Abuse Treat Prev Policy. 2022;17(1):59. DOI:10.1080/14659891.2022.2120425

Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, MacKillop J. Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: A systematic review. Alcohol Clin Exp Res. 2019;43(4):550–63. DOI: 10.1111/acer.13964

Vitale RM, Iannotti FA, Amodeo P. The (poly)pharmacology of cannabidiol in neurological and neuropsychiatric disorders: Molecular mechanisms and targets. Int J Mol Sci. 2021;22(9):4876. DOI: 10.3390/ijms22094876

Metz VG, da Rosa JLO, Rossato DR, Milanesi LH, Burger ME, Pase CS. Cannabidiol prevents amphetamine relapse and modulates D1- and D2-receptor levels in mesocorticolimbic brain areas of rats. Eur Neuropsychopharmacol. 2021;50. DOI: 10.1016/j.euroneuro

Nouri K, Anooshe M, Karimi-Haghighi S, Mousavi Z, Haghparast A. Involvement of hippocampal D1-like dopamine receptors in the inhibitory effect of cannabidiol on acquisition and expression of methamphetamine-induced conditioned place preference. Neurochem Res. 2021;46(8):2008-2018. DOI: 10.1007/s11064-021-03350-w

Rizkallah E, Mongeau-Pérusse V, Lamanuzzi L, Castenada-Ouellet SA, Stip E, Juteau LC, et al. Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. Pharmacol Biochem Behav. 2022;216:173376. DOI: 10.1016/j.pbb.2022.173376

Qian Y, Gilliland TK, Markowitz JS. The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin. Chem Biol Interact. 2020;316:108914. DOI: 10.1016/j.cbi.2019.108914

Brice-Tutt AC, Montgomery DS, Kramer CM, Novotny PM, Malphurs WL, Sharma A. An ethogram analysis of cutaneous thermal pain sensitivity and oxycodone reward-related behaviors in rats. Version 1. Res Sq [Preprint]. 2023. DOI: 10.21203/rs.3.rs-2679319/v1

Pallanti S, Marras A, Makris N. A research domain criteria approach to gambling disorder and behavioral addictions: Decision-making, response inhibition, and the role of cannabidiol. Front Psychiatry. 2021;12:634418. DOI: 10.3389/fpsyt.2021.634418

Madden K, Tanco K, Bruera E. Clinically significant drug-drug interaction between methadone and cannabidiol. Pediatrics. 2020;145(6):e20193256. DOI: 10.1542/peds.2019-3256

Darweesh RS, Khamis TN, El-Elimat T. The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(10):1871–86. DOI: 10.1007/s00210-020-01878-2

Stohs SJ, Ray D. Is cannabidiol hepatotoxic or hepatoprotective: A review. Toxicol Res Appl. 2020;4. DOI: 10.1177/2397847320922944

Flores VA, Kisiolek JN, Ramani A, Townsend R, Rodriguez E, Butler B, Stewart LK. Effects of oral cannabidiol on health and fitness in healthy adults: An 8-week randomized trial. Nutrients. 2023;15(12):2664. DOI: 10.3390/nu15122664

Matheson J, Bourgault Z, Le Foll B. Sex differences in the neuropsychiatric effects and pharmacokinetics of cannabidiol: A scoping review. Biomolecules. 2022;12(10):1462. DOI: 10.3390/biom12101462

Pandelides Z, Thornton C, Faruque AS, Whitehead AP, Willett KL, Ashpole NM. Developmental exposure to cannabidiol (CBD) alters longevity and health span of zebrafish (Danio rerio). GeroScience. 2020;42(2):785–800. DOI: 10.1007/s11357-020-00182-4

Carvalho RK, Rocha TL, Fernandes FH, Gonçalves BB, Souza MR, Araújo AA, et al. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: New insights of cannabidiol-mediated male reproductive toxicity. Chem Biol Interact. 2022;351:109743. DOI: 10.1016/j.cbi.2021.109743

Pandelides Z, Aluru N, Thornton C, Watts HE, Willett KL. transcriptomic changes and the roles of cannabinoid receptors and PPARγ in developmental toxicities following exposure to Δ9-tetrahydrocannabinol and cannabidiol. Toxicol Sci. 2021;182(1):44–59. DOI: 10.1093/toxsci/kfab046

Merrick J, Lane B, Sebree T, Yaksh T, O'Neill C, Banks SL. Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid. Cannabis Cannabinoid Res. 2016;1(1):102–12. DOI: 10.1089/can.2015.0004

Henderson RG, Franke KS, Payne LE, Franzen A. Cannabidiol safety data: A systematic mapping study. Cannabis Cannabinoid Res. 2023;8(1):34–40. DOI: 10.1089/can.2022.0100

Reece AS, Hulse GK. Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: Part 3 – spatiotemporal, multivariable and causal inferential pathfinding and exploratory analyses of prostate and ovarian cancers. Arch Public Health. 2022;80(1):101. DOI: 10.1186/s13690-022-00813-6

Madera-Acosta A, Johnson-Wall H, Carbone LD, Meszaros A, Berman AE, White J. Cannabidiol (CBD) oil toxicity mimicking extraglandular complications of Sjögren's syndrome. Rheumatol Adv Pract. 2021;5(1):rkab010. DOI: 10.1093/rap/rkab010

Dellepiane S, Paranjpe I, Rajagopal M, Kamat S, O'Hagan R, Gulamali F, et al. Cannabis use and ckd: Epidemiological associations and mendelian randomization. Kidney med. 2022;5(2):100582. DOI: 10.1016/j.xkme.2022.100582

Carmona-Hidalgo B, García-Martín A, Muñoz E, González-Mariscal I. Detrimental effect of cannabidiol on the early onset of diabetic nephropathy in male mice. Pharmaceuticals (Basel). 2021;14(9):863. DOI: 10.3390/ph14090863

Mascal M, Hafezi N, Wang D, Hu Y, Serra G, Dallas ML, Spencer JP. Synthetic, non-intoxicating 8,9-dihydrocannabidiol for the mitigation of seizures. Sci Rep. 2019;9(1):7778. DOI: 10.1038/s41598-019-44056-y

Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (cbd): Toward a new age. Front Immunol. 2018;9:2009. DOI: 10.3389/fimmu.2018.02009

Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav. 2018;88:162–71. DOI: 10.1016/j.yebeh.2018.07.027

Hunter D, Oldfield G, Tich N, Messenheimer J, Sebree T. Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis. J Osteoarthr Cartil. 2018;26(Suppl 1). DOI: 10.1016/j.joca.2018.02.067

Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Knutsen HK, et al. Statement on safety of cannabidiol as a novel food: Data gaps and uncertainties. EFSA Journal. 2022;20(6):e07322. DOI: 10.2903/j.efsa.2022.7322

Dziwenka M, Coppock R, Davidson MH, Weder MA. Toxicological safety assessment of HempChoice® hemp oil extract; a proprietary extract consisting of a high concentration of cannabidiol (CBD) in addition to other phytocannabinoids and terpenes derived from Cannabissativa L. Heliyon. 2023;9(6):e16913. DOI: 10.1016/j.heliyon.2023.e16913

Sharifi A, Karimi-Haghighi S, Shabani R, Asgari HR, Ahadi R, Haghparast A. Cannabidiol impairs the rewarding effects of methamphetamine: Involvement of dopaminergic receptors in the nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry. 2022;113:110458. DOI: 10.1016/j.pnpbp.2021.110458

Mboumba Bouassa RS, Needham J, Nohynek D, Singer J, Lee T, Bobeuf F, et al. Safety and tolerability of oral cannabinoids in people living with hiv on long-term art: A randomized, open-label, interventional pilot clinical trial (CTNPT 028). Biomedicines. 2022;10(12):3168. DOI: 10.3390/biomedicines10123168

Rein JL. The nephrologist's guide to cannabis and cannabinoids. Curr Opin Nephrol Hypertens. 2020;29(2):248–57. DOI: 10.1097/MNH.0000000000000590

Sund LJ, Dargan PI, Archer JRH, Wood DM. E-cigarette or vaping-associated lung injury (EVALI): A review of international case reports from outside the United States of America. Clin Toxicol (Phila). 2023;61(2):91–97. DOI: 10.1080/15563650.2022.2160342